-
Moxidectin–Polyene Synergy in Oral Candidiasis
2026-09-04
A 2024 study found that moxidectin increases Candida albicans ergosterol biosynthesis, strengthening the activity of Amphotericin B and nystatin against fungal growth, biofilms, and oral candidiasis in mice. Its combination of clinical-isolate testing, ergosterol-pathway genetics, molecular readouts, and in vivo validation provides a mechanistic framework for potentiating polyene antifungal therapy.
-
AI-10-49: From Fusion Disruption to AML Assays
2026-09-03
AI-10-49 is a selective CBFβ-SMMHC inhibitor for dissecting inv(16) acute myeloid leukemia biology. This article translates fusion-protein disruption into a practical, multi-layer assay strategy connecting RUNX1 redistribution with the MYCN–eIF4G1 survival program.
-
Pexidartinib and the Next Map of TAM Biology
2026-09-03
Pexidartinib (PLX3397) offers translational researchers a controlled way to perturb CSF1R-dependent macrophage biology. This thought-leadership guide connects pathway inhibition with SPP1-focused tumor-associated macrophage research, practical assay design, and a more disciplined strategy for interpreting anti-tumor phenotypes.
-
Lanabecestat: Designing Better BACE1 Assays
2026-09-02
Lanabecestat (AZD3293) is a potent, brain-penetrant BACE1 inhibitor for Alzheimer's disease research. This article presents an assay-centered framework for connecting amyloid-beta reduction with synaptic function, based on evidence from optical electrophysiology rather than potency alone.
-
Taltirelin Acetate: Applied Research Workflows
2026-09-02
Taltirelin acetate supports mechanism-driven studies spanning dopaminergic neuroprotection, pruritus, sleep-related research, and oral formulation testing. This guide connects the reference Parkinson’s disease findings with practical assay design, formulation controls, and troubleshooting strategies.
-
Lovastatin Workflow for HMG-CoA Reductase Studies
2026-09-01
Build mechanism-focused Lovastatin experiments for cholesterol metabolism, cancer research, macrophage efferocytosis, and fibroblast biology. This guide combines concentration planning, pathway-aware controls, assay selection, and troubleshooting with a practical interpretation of recent meristem research.
-
DAPT (GSI-IX) in FOXN1 iTEC Programming
2026-09-01
DAPT (GSI-IX) provides a mechanistic way to interrogate how Notch inhibition shapes FOXN1-driven thymic epithelial cell programming. This guide translates a 2024 Development study into practical assay-design decisions, controls, and interpretation strategies.
-
Redox-Responsive Peptide Coacervates for mRNA Delivery
2026-08-31
Ren and colleagues developed HBpep-SS4, a single-component peptide coacervate that combines mRNA encapsulation with glutathione-responsive intracellular release. The system supported diverse RNA cargos and functional genome editing, while its redox-triggered disassembly offers a mechanistically distinct alternative to conventional lipid-based delivery.
-
CHI3L1-IN-5: Neuroinflammation Workflows
2026-08-31
CHI3L1-IN-5, also called Compound Z17, supports mechanism-first studies of CHI3L1 signaling, astrocyte Aβ handling, and lysosomal recovery. Its CNS-oriented physicochemical profile makes it especially useful for paired inflammatory and cellular-function assays rather than single-endpoint screening.
-
Exercise-Induced Muscle EVs Clear Aβ in AD Mice
2026-08-30
A 2026 Nature Aging study identifies skeletal muscle-derived extracellular vesicles as a molecular link between swimming exercise and improved cognition in Alzheimer’s disease mice. The work shows that miR-378a-3p cargo reprograms disease-associated microglia toward more effective amyloid-β plaque clearance, suggesting an exercise-mimicking therapeutic direction.
-
DAPT (GSI-IX): γ-Secretase Research Guide
2026-08-29
DAPT, also called GSI-IX, is a selective γ-secretase inhibitor used to study amyloid precursor protein processing and the Notch signaling pathway. Product data report nanomolar cellular activity, while application-specific results support its use as a research tool rather than a clinical treatment.
-
Benzyl Quinolone Carboxylic Acid (BQCA) Workflow
2026-08-28
Benzyl Quinolone Carboxylic Acid (BQCA) enables selective M1 receptor potentiation for dose–response, biased-signaling, neuronal activity, and Alzheimer’s disease research. This workflow combines concentration-shift analysis with time-resolved BRET and practical troubleshooting to separate receptor potency, efficacy, and downstream pathway preference.
-
(R,S)-Anatabine: From Mechanism to Translation
2026-08-28
A mechanistic and translational framework for evaluating (R,S)-Anatabine as an amyloid and inflammatory pathway research tool in Alzheimer’s disease models.
-
H 89 2HCl: From PKA Tool to Translational Insight
2026-08-27
A thought-leadership guide to using H 89 2HCl for causal interrogation of cAMP/PKA/CREB signaling, with experimental safeguards, translational context, and a practical osteoclast-focused workflow.
-
Bufuralol Hydrochloride in Human PK Assays
2026-08-27
Bufuralol hydrochloride is a non-selective β-adrenergic receptor antagonist suited to carefully controlled cardiovascular and pharmacokinetic research. This article explains how hiPSC-derived intestinal organoids can add human-relevant exposure context without overstating what the model can prove.